Akumin's gross profit for the
three
months ended in Sep. 2023 was $22.6 Mil. Akumin's gross profit for the trailing twelve months (TTM) ended in Sep. 2023 was $120.0 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Akumin's gross profit for the
three
months ended in Sep. 2023 was $22.6 Mil. Akumin's Revenue for the
three
months ended in Sep. 2023 was $180.6 Mil. Therefore, Akumin's Gross Margin % for the quarter that ended in Sep. 2023 was 12.50%.
Akumin had a gross margin of 12.50% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage
During the past 8 years, the highestGross Margin % of Akumin was 22.19%. The lowest was 12.54%. And the median was 16.19%.
Akumin Gross Profit Historical Data
The historical data trend for Akumin's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Akumin's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akumin's Gross Profit Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Akumin's Gross Profit distribution charts can be found below:
* The bar in red indicates where Akumin's Gross Profit falls into.
Akumin Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Akumin's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $120.0 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Akumin's Gross Margin % for the quarter that ended in Sep. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Akumin (OTCPK:AKUMQ) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Akumin had a gross margin of 12.50% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage
Akumin Gross Profit Related Terms
Thank you for viewing the detailed overview of Akumin's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Akumin Inc is a Canada-based company that provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. The company operates in Florida, Pennsylvania, Delaware, Texas, Illinois, and Kansas. It offers physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, minimizing the cost and amount of care for patients. The company's imaging procedures include MRI, CT, positron emission tomography, ultrasound, X-ray, mammography, and other diagnostic or interventional radiology procedures. It operates in two reportable business segments: radiology and oncology. The radiology segment acconts for majority revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AKUMQ has been successfully added to your 